Skip to main content
Figure 6 | Arthritis Research & Therapy

Figure 6

From: Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation

Figure 6

The effect of disease-modifying antirheumatic drugs on antiadalimumab antidrug antibodies. At the end of treatment (2 weeks after the last injection), antiadalimumab antidrug antibodies (ADAbs) were less often observed in patients who used concomitant disease-modifying antirheumatic drugs (DMARDs) compared than in patients who did not use any DMARDs, although this finding was not statistically significant (A). However, this difference disappeared when we assessed the ‘unmasked’ antiadalimumab ADAbs at follow-up (B).

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us